pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 27·1 min read
save

CMS GLP-1 pilot shows early uptake and health benefits for seniors, signaling broader weight-loss drug access

Aug 27, 2026·read at Endpoints ↗RegulatoryPositive

CMS launched a federal pilot program to expand access to GLP-1 weight-loss medications for seniors.

After about two months, early data show that enrollment is rising and participants report improvements such as weight loss and better glycemic control.

Officials say the initial results could inform future policy decisions on broader coverage of GLP-1 therapies for older adults.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Impacts of CMS’ GLP-1 pilot program begin to take shape”

read at Endpoints ↗
91 words · retrieved Aug 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RISING
topics
GLP-1 receptor4Obesity3

related stories

  • 5h agoSwiss CDMOs and CROs ride a new wave of growth amid surge in global demandBioSpace
  • 4d agoOpinion: I studied GLP-1 use in children. The results are reassuringSTAT
  • 4d agoLilly raises diabetes weight-loss bar with amylin-Zepbound comboFierce Biotech
  • 6d agoTrump uses ‘contested’ power to cut more funding to HHSSTAT
  • Sep 24FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’BioSpace